Baicalein Induces Mitochondrial Autophagy to Prevent Parkinson's Disease in Rats via miR-30b and the SIRT1/AMPK/mTOR Pathway
Authors:
Open Access
- 14 February 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 646817
Abstract
Parkinson's disease (PD) is a prevailing neurodegenerative disorder. Baicalein has neuroprotective effects on PD animals, but its mechanism is not clarified. We explored baicalein effects on PD rats. PD rat models were established by injecting 6-hydroxydopamine into the striatum of substantia nigra on the left side of the rat brain and treated with baicalein. Dopamine (DA) content, neuronal apoptosis, neuronal injury, neuronal mitochondria, and autophagy were assessed. Baicalein-treated PD rats were treated with autophagy inhibitor 3-methyladenine to identify the role of autophagy in PD. PD rats were injected with AgomiR-30b-5p or sh-SIRT1 plasmids and treated with baicalein. PD rats elicited decreased neurological score and DA secretion of the striatum, increased neuronal apoptosis, and injury, and reduced number of mitochondria and autophagy, whereas baicalein alleviated neuronal injury and partly recovered mitochondrial dysfunction, 3-methyladenine inhibited the protection of baicalein. miR-30b-5p was elevated and SIRT1 was diminished in PD rats and inhibited by baicalein. miR-30b-5p targeted SIRT1. miR-30b-5p overexpression or SIRT1 silencing annulled the protection of baicalein. The phosphorylation level of AMPK in the substantia nigra of PD rats was decreased and mTOR was increased, whereas baicalein annulled these trends. Briefly, baicalein activated mitochondrial autophagy via miR-30b-5p and the SIRT1/AMPK/mTOR pathway, thus protecting PD rats.Keywords
This publication has 60 references indexed in Scilit:
- Development of a SPE-LC/MS/MS method for simultaneous quantification of baicalein, wogonin, oroxylin A and their glucuronides baicalin, wogonoside and oroxyloside in rats and its application to brain uptake and plasma pharmacokinetic studiesJournal of Pharmaceutical and Biomedical Analysis, 2014
- Protective and toxic roles of dopamine in Parkinson's diseaseJournal of Neurochemistry, 2014
- Parkinson s disease a reviewFrontiers in Bioscience-Scholar, 2014
- Assessment of the treatment effect of baicalein on a model of Parkinsonian tremor and elucidation of the mechanismLife Sciences, 2012
- Mitochondria: In Sickness and in HealthCell, 2012
- Baicalein reduces E46K α‐synuclein aggregation in vitro and protects cells against E46K α‐synuclein toxicity in cell models of familiar ParkinsonismJournal of Neurochemistry, 2010
- Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitroPharmacology Biochemistry and Behavior, 2009
- Functions and dysfunctions of mitochondrial dynamicsNature Reviews Molecular Cell Biology, 2007
- Dopaminergic neuronsThe International Journal of Biochemistry & Cell Biology, 2005
- The effects of the cyclosporin A, a P‐glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis studyBritish Journal of Pharmacology, 2002